nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCB1—Mitomycin—urinary bladder cancer	0.0637	0.116	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—urinary bladder cancer	0.0519	0.0945	CbGbCtD
Dabrafenib—ABCG2—Fluorouracil—urinary bladder cancer	0.0435	0.0793	CbGbCtD
Dabrafenib—ABCG2—Carboplatin—urinary bladder cancer	0.0433	0.0788	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—urinary bladder cancer	0.037	0.0673	CbGbCtD
Dabrafenib—ABCG2—Etoposide—urinary bladder cancer	0.0363	0.0662	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—urinary bladder cancer	0.0302	0.055	CbGbCtD
Dabrafenib—CYP3A4—Thiotepa—urinary bladder cancer	0.0289	0.0527	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—urinary bladder cancer	0.0279	0.0508	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—urinary bladder cancer	0.0248	0.0451	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—urinary bladder cancer	0.024	0.0437	CbGbCtD
Dabrafenib—CYP2C8—Fluorouracil—urinary bladder cancer	0.0232	0.0422	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—urinary bladder cancer	0.0194	0.0354	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—urinary bladder cancer	0.0193	0.0352	CbGbCtD
Dabrafenib—ABCB1—Gemcitabine—urinary bladder cancer	0.0183	0.0334	CbGbCtD
Dabrafenib—ABCB1—Cisplatin—urinary bladder cancer	0.0133	0.0243	CbGbCtD
Dabrafenib—ABCB1—Etoposide—urinary bladder cancer	0.0131	0.0239	CbGbCtD
Dabrafenib—NEK11—prostate gland—urinary bladder cancer	0.00988	0.106	CbGeAlD
Dabrafenib—ABCB1—Doxorubicin—urinary bladder cancer	0.00893	0.0163	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—urinary bladder cancer	0.00865	0.0158	CbGbCtD
Dabrafenib—CYP3A4—Etoposide—urinary bladder cancer	0.00785	0.0143	CbGbCtD
Dabrafenib—LIMK1—prostate gland—urinary bladder cancer	0.00707	0.0759	CbGeAlD
Dabrafenib—NEK11—female reproductive system—urinary bladder cancer	0.00539	0.0579	CbGeAlD
Dabrafenib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00535	0.00975	CbGbCtD
Dabrafenib—SLC22A8—urine—urinary bladder cancer	0.00471	0.0506	CbGeAlD
Dabrafenib—BRAF—prostate gland—urinary bladder cancer	0.00437	0.0469	CbGeAlD
Dabrafenib—SIK1—prostate gland—urinary bladder cancer	0.00366	0.0393	CbGeAlD
Dabrafenib—LIMK1—vagina—urinary bladder cancer	0.00349	0.0375	CbGeAlD
Dabrafenib—NEK11—lymph node—urinary bladder cancer	0.00315	0.0339	CbGeAlD
Dabrafenib—RAF1—prostate gland—urinary bladder cancer	0.00291	0.0313	CbGeAlD
Dabrafenib—SIK1—renal system—urinary bladder cancer	0.00249	0.0268	CbGeAlD
Dabrafenib—RAF1—seminal vesicle—urinary bladder cancer	0.00246	0.0264	CbGeAlD
Dabrafenib—SIK1—urethra—urinary bladder cancer	0.00245	0.0263	CbGeAlD
Dabrafenib—CYP3A4—urine—urinary bladder cancer	0.00234	0.0251	CbGeAlD
Dabrafenib—LIMK1—lymph node—urinary bladder cancer	0.00226	0.0242	CbGeAlD
Dabrafenib—BRAF—vagina—urinary bladder cancer	0.00216	0.0232	CbGeAlD
Dabrafenib—RAF1—epithelium—urinary bladder cancer	0.00214	0.023	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—urinary bladder cancer	0.00206	0.0221	CbGeAlD
Dabrafenib—SIK1—female reproductive system—urinary bladder cancer	0.002	0.0214	CbGeAlD
Dabrafenib—RAF1—renal system—urinary bladder cancer	0.00198	0.0213	CbGeAlD
Dabrafenib—RAF1—urethra—urinary bladder cancer	0.00195	0.0209	CbGeAlD
Dabrafenib—SLCO1B3—vagina—urinary bladder cancer	0.00186	0.02	CbGeAlD
Dabrafenib—SLC22A8—prostate gland—urinary bladder cancer	0.00169	0.0182	CbGeAlD
Dabrafenib—RAF1—female reproductive system—urinary bladder cancer	0.00159	0.0171	CbGeAlD
Dabrafenib—SLCO1B1—renal system—urinary bladder cancer	0.00148	0.0159	CbGeAlD
Dabrafenib—RAF1—vagina—urinary bladder cancer	0.00144	0.0154	CbGeAlD
Dabrafenib—BRAF—lymph node—urinary bladder cancer	0.00139	0.015	CbGeAlD
Dabrafenib—ABCG2—prostate gland—urinary bladder cancer	0.0012	0.0129	CbGeAlD
Dabrafenib—SLCO1B1—female reproductive system—urinary bladder cancer	0.00119	0.0128	CbGeAlD
Dabrafenib—SIK1—lymph node—urinary bladder cancer	0.00117	0.0125	CbGeAlD
Dabrafenib—SLC22A8—renal system—urinary bladder cancer	0.00115	0.0124	CbGeAlD
Dabrafenib—ABCG2—seminal vesicle—urinary bladder cancer	0.00102	0.0109	CbGeAlD
Dabrafenib—RAF1—lymph node—urinary bladder cancer	0.000929	0.00998	CbGeAlD
Dabrafenib—CYP2C8—renal system—urinary bladder cancer	0.000844	0.00906	CbGeAlD
Dabrafenib—ABCG2—urethra—urinary bladder cancer	0.000806	0.00866	CbGeAlD
Dabrafenib—CYP2C8—female reproductive system—urinary bladder cancer	0.000676	0.00726	CbGeAlD
Dabrafenib—CYP2C8—vagina—urinary bladder cancer	0.000611	0.00656	CbGeAlD
Dabrafenib—ABCG2—vagina—urinary bladder cancer	0.000594	0.00638	CbGeAlD
Dabrafenib—ABCB1—prostate gland—urinary bladder cancer	0.000594	0.00638	CbGeAlD
Dabrafenib—CYP3A4—renal system—urinary bladder cancer	0.000572	0.00614	CbGeAlD
Dabrafenib—ABCB1—seminal vesicle—urinary bladder cancer	0.000502	0.00539	CbGeAlD
Dabrafenib—CYP3A4—female reproductive system—urinary bladder cancer	0.000458	0.00492	CbGeAlD
Dabrafenib—ABCB1—epithelium—urinary bladder cancer	0.000436	0.00468	CbGeAlD
Dabrafenib—ABCB1—renal system—urinary bladder cancer	0.000405	0.00435	CbGeAlD
Dabrafenib—ABCB1—urethra—urinary bladder cancer	0.000397	0.00427	CbGeAlD
Dabrafenib—ABCG2—lymph node—urinary bladder cancer	0.000384	0.00413	CbGeAlD
Dabrafenib—ABCB1—female reproductive system—urinary bladder cancer	0.000324	0.00348	CbGeAlD
Dabrafenib—ABCB1—vagina—urinary bladder cancer	0.000293	0.00315	CbGeAlD
Dabrafenib—Constipation—Gemcitabine—urinary bladder cancer	0.000191	0.00097	CcSEcCtD
Dabrafenib—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00019	0.00097	CcSEcCtD
Dabrafenib—Asthenia—Thiotepa—urinary bladder cancer	0.00019	0.000968	CcSEcCtD
Dabrafenib—ABCB1—lymph node—urinary bladder cancer	0.00019	0.00204	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000189	0.000964	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000189	0.000963	CcSEcCtD
Dabrafenib—Infection—Etoposide—urinary bladder cancer	0.000189	0.000963	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000188	0.000958	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—urinary bladder cancer	0.000187	0.000954	CcSEcCtD
Dabrafenib—Pruritus—Thiotepa—urinary bladder cancer	0.000187	0.000954	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—urinary bladder cancer	0.000187	0.000951	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000186	0.000949	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—urinary bladder cancer	0.000185	0.000941	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—urinary bladder cancer	0.000184	0.000937	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000184	0.000937	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—urinary bladder cancer	0.000184	0.000936	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000183	0.000934	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000183	0.000931	CcSEcCtD
Dabrafenib—Diarrhoea—Thiotepa—urinary bladder cancer	0.000181	0.000923	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000181	0.000921	CcSEcCtD
Dabrafenib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000181	0.000919	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00018	0.000914	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000179	0.000913	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—urinary bladder cancer	0.000179	0.00091	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—urinary bladder cancer	0.000179	0.00091	CcSEcCtD
Dabrafenib—Hypotension—Etoposide—urinary bladder cancer	0.000178	0.000905	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000177	0.000902	CcSEcCtD
Dabrafenib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000176	0.000897	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—urinary bladder cancer	0.000176	0.000895	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—urinary bladder cancer	0.000175	0.000893	CcSEcCtD
Dabrafenib—Dizziness—Thiotepa—urinary bladder cancer	0.000175	0.000892	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—urinary bladder cancer	0.000174	0.000887	CcSEcCtD
Dabrafenib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000173	0.000882	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—urinary bladder cancer	0.00017	0.000868	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00017	0.000866	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000169	0.000862	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—urinary bladder cancer	0.000169	0.000858	CcSEcCtD
Dabrafenib—Vomiting—Thiotepa—urinary bladder cancer	0.000168	0.000858	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—urinary bladder cancer	0.000167	0.000852	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—urinary bladder cancer	0.000167	0.000852	CcSEcCtD
Dabrafenib—Rash—Thiotepa—urinary bladder cancer	0.000167	0.000851	CcSEcCtD
Dabrafenib—Dermatitis—Thiotepa—urinary bladder cancer	0.000167	0.00085	CcSEcCtD
Dabrafenib—Headache—Thiotepa—urinary bladder cancer	0.000166	0.000845	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—urinary bladder cancer	0.000165	0.000842	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—urinary bladder cancer	0.000164	0.000837	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000164	0.000837	CcSEcCtD
Dabrafenib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000164	0.000836	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—urinary bladder cancer	0.000164	0.000835	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—urinary bladder cancer	0.000163	0.00083	CcSEcCtD
Dabrafenib—Constipation—Etoposide—urinary bladder cancer	0.000163	0.000829	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000163	0.000828	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—urinary bladder cancer	0.000162	0.000826	CcSEcCtD
Dabrafenib—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000161	0.000822	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—urinary bladder cancer	0.000161	0.000821	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—urinary bladder cancer	0.00016	0.000817	CcSEcCtD
Dabrafenib—Asthenia—Gemcitabine—urinary bladder cancer	0.00016	0.000814	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—urinary bladder cancer	0.000159	0.000812	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000158	0.000807	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—urinary bladder cancer	0.000158	0.000803	CcSEcCtD
Dabrafenib—Pruritus—Gemcitabine—urinary bladder cancer	0.000158	0.000803	CcSEcCtD
Dabrafenib—Nausea—Thiotepa—urinary bladder cancer	0.000157	0.000801	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—urinary bladder cancer	0.000157	0.000801	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000157	0.000797	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000156	0.000792	CcSEcCtD
Dabrafenib—Pruritus—Fluorouracil—urinary bladder cancer	0.000155	0.000789	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000155	0.000788	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—urinary bladder cancer	0.000155	0.000788	CcSEcCtD
Dabrafenib—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000153	0.000779	CcSEcCtD
Dabrafenib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000152	0.000776	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—urinary bladder cancer	0.000152	0.000775	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—urinary bladder cancer	0.000151	0.000768	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—urinary bladder cancer	0.000151	0.000768	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—urinary bladder cancer	0.00015	0.000766	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—urinary bladder cancer	0.00015	0.000766	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00015	0.000766	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—urinary bladder cancer	0.00015	0.000764	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—urinary bladder cancer	0.00015	0.000763	CcSEcCtD
Dabrafenib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00015	0.000763	CcSEcCtD
Dabrafenib—Asthenia—Cisplatin—urinary bladder cancer	0.000149	0.000759	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000148	0.000755	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000148	0.000753	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—urinary bladder cancer	0.000148	0.000751	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000148	0.000751	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—urinary bladder cancer	0.000147	0.000749	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—urinary bladder cancer	0.000146	0.000743	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—urinary bladder cancer	0.000146	0.000741	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—urinary bladder cancer	0.000145	0.000738	CcSEcCtD
Dabrafenib—Dizziness—Fluorouracil—urinary bladder cancer	0.000145	0.000738	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000145	0.000736	CcSEcCtD
Dabrafenib—Chills—Methotrexate—urinary bladder cancer	0.000144	0.000733	CcSEcCtD
Dabrafenib—Diarrhoea—Cisplatin—urinary bladder cancer	0.000142	0.000724	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—urinary bladder cancer	0.000142	0.000722	CcSEcCtD
Dabrafenib—Vomiting—Gemcitabine—urinary bladder cancer	0.000142	0.000721	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—urinary bladder cancer	0.000141	0.000716	CcSEcCtD
Dabrafenib—Rash—Gemcitabine—urinary bladder cancer	0.000141	0.000715	CcSEcCtD
Dabrafenib—Dermatitis—Gemcitabine—urinary bladder cancer	0.00014	0.000715	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—urinary bladder cancer	0.00014	0.000714	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—urinary bladder cancer	0.00014	0.000714	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—urinary bladder cancer	0.00014	0.000711	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—urinary bladder cancer	0.00014	0.000711	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00014	0.000711	CcSEcCtD
Dabrafenib—Headache—Gemcitabine—urinary bladder cancer	0.00014	0.000711	CcSEcCtD
Dabrafenib—Vomiting—Fluorouracil—urinary bladder cancer	0.000139	0.000709	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000139	0.000707	CcSEcCtD
Dabrafenib—Rash—Fluorouracil—urinary bladder cancer	0.000138	0.000703	CcSEcCtD
Dabrafenib—Dermatitis—Fluorouracil—urinary bladder cancer	0.000138	0.000703	CcSEcCtD
Dabrafenib—Headache—Fluorouracil—urinary bladder cancer	0.000137	0.000699	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000137	0.000699	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000137	0.000697	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—urinary bladder cancer	0.000137	0.000695	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000137	0.000695	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—urinary bladder cancer	0.000136	0.000694	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000136	0.000693	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—urinary bladder cancer	0.000136	0.000691	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000135	0.000689	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—urinary bladder cancer	0.000135	0.000688	CcSEcCtD
Dabrafenib—Chills—Epirubicin—urinary bladder cancer	0.000135	0.000686	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—urinary bladder cancer	0.000135	0.000686	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—urinary bladder cancer	0.000134	0.000683	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—urinary bladder cancer	0.000133	0.000676	CcSEcCtD
Dabrafenib—Nausea—Gemcitabine—urinary bladder cancer	0.000132	0.000674	CcSEcCtD
Dabrafenib—Vomiting—Cisplatin—urinary bladder cancer	0.000132	0.000672	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—urinary bladder cancer	0.000132	0.00067	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—urinary bladder cancer	0.000132	0.00067	CcSEcCtD
Dabrafenib—Rash—Cisplatin—urinary bladder cancer	0.000131	0.000667	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—urinary bladder cancer	0.000131	0.000666	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—urinary bladder cancer	0.000131	0.000665	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—urinary bladder cancer	0.000131	0.000665	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—urinary bladder cancer	0.00013	0.000663	CcSEcCtD
Dabrafenib—Nausea—Fluorouracil—urinary bladder cancer	0.00013	0.000663	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—urinary bladder cancer	0.00013	0.000661	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—urinary bladder cancer	0.000129	0.000657	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—urinary bladder cancer	0.000126	0.000644	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—urinary bladder cancer	0.000126	0.000642	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—urinary bladder cancer	0.000126	0.000641	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—urinary bladder cancer	0.000126	0.00064	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000125	0.000639	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000125	0.000638	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—urinary bladder cancer	0.000125	0.000637	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—urinary bladder cancer	0.000125	0.000635	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000124	0.000632	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—urinary bladder cancer	0.000123	0.000628	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—urinary bladder cancer	0.000123	0.000627	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—urinary bladder cancer	0.000123	0.000625	CcSEcCtD
Dabrafenib—Cough—Methotrexate—urinary bladder cancer	0.000122	0.000621	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—urinary bladder cancer	0.000122	0.00062	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—urinary bladder cancer	0.000121	0.000616	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—urinary bladder cancer	0.000121	0.000616	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—urinary bladder cancer	0.000121	0.000616	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—urinary bladder cancer	0.000121	0.000615	CcSEcCtD
Dabrafenib—Rash—Etoposide—urinary bladder cancer	0.00012	0.000611	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—urinary bladder cancer	0.00012	0.00061	CcSEcCtD
Dabrafenib—Headache—Etoposide—urinary bladder cancer	0.000119	0.000607	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—urinary bladder cancer	0.000119	0.000605	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—urinary bladder cancer	0.000119	0.000605	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000118	0.000601	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—urinary bladder cancer	0.000117	0.000596	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—urinary bladder cancer	0.000117	0.000596	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000116	0.000592	CcSEcCtD
Dabrafenib—Cough—Epirubicin—urinary bladder cancer	0.000114	0.000581	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—urinary bladder cancer	0.000114	0.00058	CcSEcCtD
Dabrafenib—Infection—Methotrexate—urinary bladder cancer	0.000113	0.000577	CcSEcCtD
Dabrafenib—Nausea—Etoposide—urinary bladder cancer	0.000113	0.000576	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—urinary bladder cancer	0.000113	0.000575	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000112	0.000569	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—urinary bladder cancer	0.000112	0.000569	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000112	0.000568	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—urinary bladder cancer	0.000111	0.000567	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—urinary bladder cancer	0.000111	0.000567	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—urinary bladder cancer	0.000111	0.000564	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000111	0.000563	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00011	0.000561	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—urinary bladder cancer	0.000109	0.000554	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—urinary bladder cancer	0.000108	0.000551	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—urinary bladder cancer	0.000107	0.000543	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—urinary bladder cancer	0.000107	0.000542	CcSEcCtD
Dabrafenib—Infection—Epirubicin—urinary bladder cancer	0.000106	0.00054	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—urinary bladder cancer	0.000106	0.000537	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000105	0.000533	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000104	0.000532	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—urinary bladder cancer	0.000104	0.000532	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000104	0.000529	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—urinary bladder cancer	0.000104	0.000528	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000103	0.000525	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—urinary bladder cancer	0.000103	0.000525	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—urinary bladder cancer	0.000103	0.000524	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—urinary bladder cancer	0.000103	0.000524	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000102	0.000521	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—urinary bladder cancer	0.000101	0.000513	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—urinary bladder cancer	9.97e-05	0.000508	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—urinary bladder cancer	9.91e-05	0.000505	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—urinary bladder cancer	9.87e-05	0.000503	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.84e-05	0.000501	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—urinary bladder cancer	9.83e-05	0.0005	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—urinary bladder cancer	9.81e-05	0.000499	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.72e-05	0.000495	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.68e-05	0.000493	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.66e-05	0.000492	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—urinary bladder cancer	9.65e-05	0.000491	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—urinary bladder cancer	9.59e-05	0.000488	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.54e-05	0.000486	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.32e-05	0.000475	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—urinary bladder cancer	9.27e-05	0.000472	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—urinary bladder cancer	9.22e-05	0.00047	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	9.21e-05	0.000469	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—urinary bladder cancer	9.2e-05	0.000468	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—urinary bladder cancer	9.12e-05	0.000464	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—urinary bladder cancer	9.01e-05	0.000459	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—urinary bladder cancer	9.01e-05	0.000459	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.99e-05	0.000458	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—urinary bladder cancer	8.93e-05	0.000455	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.72e-05	0.000444	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—urinary bladder cancer	8.58e-05	0.000437	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.52e-05	0.000434	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—urinary bladder cancer	8.51e-05	0.000433	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—urinary bladder cancer	8.44e-05	0.00043	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—urinary bladder cancer	8.43e-05	0.000429	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—urinary bladder cancer	8.43e-05	0.000429	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—urinary bladder cancer	8.4e-05	0.000428	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—urinary bladder cancer	8.18e-05	0.000416	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	8.07e-05	0.000411	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—urinary bladder cancer	8.06e-05	0.000411	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—urinary bladder cancer	7.86e-05	0.0004	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—urinary bladder cancer	7.8e-05	0.000397	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—urinary bladder cancer	7.8e-05	0.000397	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—urinary bladder cancer	7.8e-05	0.000397	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—urinary bladder cancer	7.65e-05	0.00039	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—urinary bladder cancer	7.55e-05	0.000384	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—urinary bladder cancer	7.54e-05	0.000384	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—urinary bladder cancer	7.3e-05	0.000372	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.27e-05	0.00037	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—urinary bladder cancer	7.25e-05	0.000369	CcSEcCtD
Dabrafenib—Rash—Methotrexate—urinary bladder cancer	7.19e-05	0.000366	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—urinary bladder cancer	7.18e-05	0.000366	CcSEcCtD
Dabrafenib—Headache—Methotrexate—urinary bladder cancer	7.14e-05	0.000364	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—urinary bladder cancer	7.08e-05	0.000361	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—urinary bladder cancer	7.05e-05	0.000359	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—urinary bladder cancer	6.98e-05	0.000356	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—urinary bladder cancer	6.78e-05	0.000345	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—urinary bladder cancer	6.77e-05	0.000345	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—urinary bladder cancer	6.75e-05	0.000344	CcSEcCtD
Dabrafenib—Rash—Epirubicin—urinary bladder cancer	6.73e-05	0.000342	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—urinary bladder cancer	6.72e-05	0.000342	CcSEcCtD
Dabrafenib—Headache—Epirubicin—urinary bladder cancer	6.68e-05	0.00034	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—urinary bladder cancer	6.53e-05	0.000332	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—urinary bladder cancer	6.34e-05	0.000323	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—urinary bladder cancer	6.28e-05	0.00032	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—urinary bladder cancer	6.22e-05	0.000317	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—urinary bladder cancer	6.22e-05	0.000317	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—urinary bladder cancer	6.18e-05	0.000315	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—urinary bladder cancer	5.86e-05	0.000299	CcSEcCtD
Dabrafenib—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.29e-05	0.000142	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—S100B—urinary bladder cancer	2.27e-05	0.000141	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GPX1—urinary bladder cancer	2.27e-05	0.000141	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—KRAS—urinary bladder cancer	2.25e-05	0.000139	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.23e-05	0.000138	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	2.23e-05	0.000138	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.18e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—urinary bladder cancer	2.18e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RBX1—urinary bladder cancer	2.17e-05	0.000134	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.17e-05	0.000134	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ERBB2—urinary bladder cancer	2.17e-05	0.000134	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—urinary bladder cancer	2.16e-05	0.000133	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	2.15e-05	0.000133	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.11e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—urinary bladder cancer	2.11e-05	0.000131	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.11e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—urinary bladder cancer	2.1e-05	0.00013	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	2.1e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB2—urinary bladder cancer	2.08e-05	0.000129	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.08e-05	0.000129	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.06e-05	0.000127	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.05e-05	0.000127	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NCOR1—urinary bladder cancer	2.04e-05	0.000127	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSC1—urinary bladder cancer	2.04e-05	0.000126	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—urinary bladder cancer	2.03e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NCOR1—urinary bladder cancer	2.02e-05	0.000125	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.02e-05	0.000125	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.01e-05	0.000124	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CREBBP—urinary bladder cancer	2.01e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EP300—urinary bladder cancer	1.99e-05	0.000123	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.97e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—EP300—urinary bladder cancer	1.96e-05	0.000121	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.96e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JAG1—urinary bladder cancer	1.94e-05	0.00012	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—SRC—urinary bladder cancer	1.94e-05	0.00012	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NQO1—urinary bladder cancer	1.92e-05	0.000119	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.92e-05	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—urinary bladder cancer	1.91e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SRC—urinary bladder cancer	1.9e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERCC2—urinary bladder cancer	1.9e-05	0.000118	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.85e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1A—urinary bladder cancer	1.85e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PTEN—urinary bladder cancer	1.85e-05	0.000114	CbGpPWpGaD
Dabrafenib—BRAF—Disease—RHOA—urinary bladder cancer	1.82e-05	0.000113	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.82e-05	0.000112	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.82e-05	0.000112	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TERT—urinary bladder cancer	1.8e-05	0.000112	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.79e-05	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—urinary bladder cancer	1.78e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TERT—urinary bladder cancer	1.78e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1A—urinary bladder cancer	1.78e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PTEN—urinary bladder cancer	1.77e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR3—urinary bladder cancer	1.77e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EP300—urinary bladder cancer	1.76e-05	0.000109	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.76e-05	0.000109	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.75e-05	0.000108	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	1.73e-05	0.000107	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.71e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—SRC—urinary bladder cancer	1.71e-05	0.000106	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	1.7e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—urinary bladder cancer	1.7e-05	0.000105	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB2—urinary bladder cancer	1.68e-05	0.000104	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.68e-05	0.000104	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.66e-05	0.000103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR3—urinary bladder cancer	1.65e-05	0.000102	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—urinary bladder cancer	1.65e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—SRC—urinary bladder cancer	1.64e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR3—urinary bladder cancer	1.63e-05	0.000101	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	1.63e-05	0.000101	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.63e-05	0.000101	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.62e-05	0.0001	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—urinary bladder cancer	1.62e-05	0.0001	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.61e-05	0.0001	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.61e-05	9.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ESR1—urinary bladder cancer	1.61e-05	9.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—urinary bladder cancer	1.61e-05	9.94e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—urinary bladder cancer	1.61e-05	9.94e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.6e-05	9.91e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.59e-05	9.86e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.59e-05	9.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—urinary bladder cancer	1.57e-05	9.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—S100B—urinary bladder cancer	1.57e-05	9.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.53e-05	9.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CREBBP—urinary bladder cancer	1.51e-05	9.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—urinary bladder cancer	1.5e-05	9.29e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.5e-05	9.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.5e-05	9.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—urinary bladder cancer	1.49e-05	9.25e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TYMS—urinary bladder cancer	1.49e-05	9.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—RHOA—urinary bladder cancer	1.49e-05	9.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.48e-05	9.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.48e-05	9.17e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	9.13e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	9.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.47e-05	9.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—urinary bladder cancer	1.44e-05	8.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.44e-05	8.91e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1A—urinary bladder cancer	1.44e-05	8.9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	8.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—urinary bladder cancer	1.44e-05	8.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—urinary bladder cancer	1.42e-05	8.78e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.42e-05	8.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NCOR1—urinary bladder cancer	1.41e-05	8.75e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GPX1—urinary bladder cancer	1.41e-05	8.75e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.41e-05	8.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.41e-05	8.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CREBBP—urinary bladder cancer	1.41e-05	8.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—urinary bladder cancer	1.4e-05	8.66e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.39e-05	8.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CREBBP—urinary bladder cancer	1.39e-05	8.61e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1—urinary bladder cancer	1.39e-05	8.6e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ERCC2—urinary bladder cancer	1.39e-05	8.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.38e-05	8.52e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EP300—urinary bladder cancer	1.37e-05	8.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—urinary bladder cancer	1.36e-05	8.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—urinary bladder cancer	1.36e-05	8.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—urinary bladder cancer	1.34e-05	8.29e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	1.34e-05	8.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SRC—urinary bladder cancer	1.33e-05	8.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.31e-05	8.1e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—urinary bladder cancer	1.3e-05	8.07e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.29e-05	7.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.29e-05	7.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RHOA—urinary bladder cancer	1.27e-05	7.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—urinary bladder cancer	1.26e-05	7.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—RHOA—urinary bladder cancer	1.26e-05	7.79e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.25e-05	7.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—urinary bladder cancer	1.25e-05	7.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—urinary bladder cancer	1.25e-05	7.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—urinary bladder cancer	1.21e-05	7.46e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—urinary bladder cancer	1.19e-05	7.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—urinary bladder cancer	1.18e-05	7.3e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.17e-05	7.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—urinary bladder cancer	1.17e-05	7.22e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	1.17e-05	7.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—urinary bladder cancer	1.16e-05	7.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.16e-05	7.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—urinary bladder cancer	1.16e-05	7.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR3—urinary bladder cancer	1.14e-05	7.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—urinary bladder cancer	1.14e-05	7.08e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.14e-05	7.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—urinary bladder cancer	1.14e-05	7.05e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—urinary bladder cancer	1.12e-05	6.92e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—urinary bladder cancer	1.11e-05	6.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—urinary bladder cancer	1.11e-05	6.88e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—urinary bladder cancer	1.1e-05	6.82e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.1e-05	6.81e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.1e-05	6.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—urinary bladder cancer	1.08e-05	6.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—urinary bladder cancer	1.08e-05	6.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—urinary bladder cancer	1.07e-05	6.61e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.06e-05	6.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—urinary bladder cancer	1.04e-05	6.45e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.04e-05	6.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—urinary bladder cancer	1.03e-05	6.35e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	6.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—urinary bladder cancer	1.01e-05	6.26e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.01e-05	6.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—urinary bladder cancer	1.01e-05	6.24e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—urinary bladder cancer	1.01e-05	6.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—urinary bladder cancer	9.97e-06	6.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	9.96e-06	6.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—urinary bladder cancer	9.95e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	9.95e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—urinary bladder cancer	9.93e-06	6.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREBBP—urinary bladder cancer	9.74e-06	6.03e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.64e-06	5.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—urinary bladder cancer	9.62e-06	5.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—urinary bladder cancer	9.58e-06	5.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—urinary bladder cancer	9.57e-06	5.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—urinary bladder cancer	9.47e-06	5.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—urinary bladder cancer	9.37e-06	5.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—urinary bladder cancer	9.32e-06	5.77e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—urinary bladder cancer	9.26e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—urinary bladder cancer	9.21e-06	5.7e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	9.16e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	9.16e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—urinary bladder cancer	9.04e-06	5.59e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	8.98e-06	5.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RHOA—urinary bladder cancer	8.81e-06	5.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—urinary bladder cancer	8.77e-06	5.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—urinary bladder cancer	8.74e-06	5.41e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	8.68e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	8.61e-06	5.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	8.59e-06	5.32e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—urinary bladder cancer	8.35e-06	5.17e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	8.32e-06	5.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—urinary bladder cancer	8.26e-06	5.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—urinary bladder cancer	8.25e-06	5.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—urinary bladder cancer	8.17e-06	5.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—urinary bladder cancer	8.15e-06	5.05e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	8.09e-06	5.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—urinary bladder cancer	8.07e-06	5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—urinary bladder cancer	8.07e-06	4.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	7.98e-06	4.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	7.98e-06	4.94e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.95e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.95e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	7.83e-06	4.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—urinary bladder cancer	7.73e-06	4.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—urinary bladder cancer	7.72e-06	4.78e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	7.72e-06	4.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—urinary bladder cancer	7.68e-06	4.76e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—urinary bladder cancer	7.64e-06	4.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—urinary bladder cancer	7.62e-06	4.72e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	7.5e-06	4.64e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—urinary bladder cancer	7.47e-06	4.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—urinary bladder cancer	7.39e-06	4.57e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—urinary bladder cancer	7.25e-06	4.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—urinary bladder cancer	7.2e-06	4.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	7.05e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—urinary bladder cancer	7.02e-06	4.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—urinary bladder cancer	6.99e-06	4.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.97e-06	4.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—urinary bladder cancer	6.95e-06	4.3e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—urinary bladder cancer	6.92e-06	4.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—urinary bladder cancer	6.86e-06	4.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—urinary bladder cancer	6.63e-06	4.1e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—urinary bladder cancer	6.56e-06	4.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—urinary bladder cancer	6.56e-06	4.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—urinary bladder cancer	6.48e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—urinary bladder cancer	6.45e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.41e-06	3.97e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	6.3e-06	3.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—urinary bladder cancer	5.78e-06	3.58e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—urinary bladder cancer	5.72e-06	3.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—urinary bladder cancer	5.65e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	5.49e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.35e-06	3.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—urinary bladder cancer	5.34e-06	3.31e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	5.16e-06	3.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.97e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.91e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.91e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—urinary bladder cancer	4.75e-06	2.94e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.71e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.62e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—urinary bladder cancer	4.54e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—urinary bladder cancer	4.5e-06	2.79e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	4.5e-06	2.78e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.34e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—urinary bladder cancer	4.29e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.92e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—urinary bladder cancer	3.74e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.52e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.38e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.77e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.42e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.3e-06	1.43e-05	CbGpPWpGaD
